Day One Biopharmaceuticals Inc (DAWN)


Stock Price Forecast

Feb. 7, 2023


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Day One Biopharmaceuticals Inc chart...

About the Company

Day One Biopharmaceuticals is a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for patients of all ages with genomically defined cancers. Day One was founded to address a critical unmet need: children with cancer are being left behind in a cancer drug development revolution. Its name was inspired by the “The Day One Talk”1 that physicians have with patients and their families about an initial cancer diagnosis and treatment plan. The company aims to re-envision cancer drug development and redefine what’s possible for all people living with cancer—regardless of age—starting from Day One. Day One partners with leading clinical oncologists, families, and scientists to identify, acquire, and develop important emerging cancer treatments. The Company’s lead product candidate, DAY101, is an oral, highly-selective type II pan-RAF kinase inhibitor, and is being evaluated in a pivotal Phase 2 clinical trial (FIREFLY-1) in pediatric, adolescent and young adult patients with recurrent or progressive low-grade glioma (pLGG). The Company’s pipeline also includes the investigational agent pimasertib, a clinical-stage, oral, small molecule found to selectively inhibit mitogen-activated protein kinase kinases 1 and 2 (MEK). Through Day One and its collaborators, cancer drug development comes of age. Day One is based in South San Francisco.

CEO

Jeremy Bender

Exchange

NASDAQ

Website

dayonebio.com

$M

Total Revenue

55

Employees

$2B

Market Capitalization

-5.90

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $DAWN News

Day One Biopharmaceuticals, Inc. (DAWN)

21d ago, source: Yahoo Finance

Overall score is calculated based on proprietary scores based on sector averages in key company indicators: fair value, dividends, innovation, hiring, and insider sentiment. Note: if you don't see ...

Day One Biopharmaceuticals Shares Rise 26% On Positive Tovorafenib Data

29d ago, source: MarketWatch

Day One Biopharmaceuticals Inc. shares were up 26% to $26.96 in premarket trading, after the company said it saw positive topline results from an ongoing Phase 2 trial evaluating the ...

DAWN.O - | Stock Price & Latest News | Reuters

16d ago, source: Reuters

Day One Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing targeted therapies for patients of all ages with genomically-defined ...

Day One Biopharma Shares Rise 13% After Positive Topline Results for Tovorafenib

29d ago, source: Morningstar%2c Inc.

Day One Biopharmaceuticals Inc. shares were up 13% to $24.11 after the company said it saw positive topline results from an ongoing Phase 2 trial evaluating the investigational agent tovorafenib.

Day One Biopharmaceuticals Shares Jump As Pediatric Brain Cancer Candidate Shows Encouraging Responses

29d ago, source: Yahoo

Day One Biopharmaceuticals (NASDAQ: DAWN) announced topline results from the ongoing Phase 2 FIREFLY-1 trial evaluating tovorafenib (DAY101) as a monotherapy in recurrent or progressive pediatric ...

Day One says drug shrinks tumors in common pediatric brain cancer, setting up potential approval

27d ago, source: STAT

Day One Biopharmaceuticals said Sunday that a targeted therapy shrank tumors by at least 50% in a majority of children with the most common form of pediatric brain cancer, setting up a potential ...

Day One stock surges 20% as brain tumor drug shows promise in mid-stage study

29d ago, source: Seeking Alpha

Day One Biopharmaceuticals (NASDAQ:DAWN) reported data from an ongoing phase 2 trial of tovorafenib to treat recurrent or progressive pediatric low-grade glioma (pLGG). The main goal of the study ...

Analysts Conflicted on These Healthcare Names: Roche Holding AG (OtherRHHVF), Enanta Pharmaceuticals (ENTA) and Day One Biopharmaceuticals (DAWN)

29d ago, source: Business Insider

Currently, the analyst consensus on Day One Biopharmaceuticals is a Strong Buy with an average price target of $40.71, implying a 92.1% upside from current levels. In a report released yesterday ...

Day One Biopharmaceuticals Inc.

26d ago, source: Wall Street Journal

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Day One Biopharmaceuticals Shares Jump As Pediatric Brain Cancer Candidate Shows Encouraging Responses

29d ago, source: MSN

© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved. Trending: Obama Says Republicans Are 'Obsessed' With 2 Things — One Of Them ...

Day One Biopharmaceuticals Inc.

12d ago, source: Barron's

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...